Blog Profile / The Medicine Show

Filed Under:Industries / Medical
Posts on Regator:1053
Posts / Week:2.9
Archived Since:February 24, 2011

Blog Post Archive

Roche To Buy Big Data Upstart Flatiron Health For $1.9 Billion

The startup, headed by Forbes 30 Under 30 list alumni Nat Turner, is going to get a lot more resources to devote to its mission of shaking up how clinical trials are conducted.

Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer

Celularity, a company spun out of biotech giant Celgene, announced this morning it has raised $250 million with the aim of developing cells from placentas to attack tumors and to treat Crohn’s disease. In addition to being awash in cash, the company is flooded with big dreams.

Bristol-Myers To Pay Largest Fee In Biotech History For Nektar Cancer Drug

Bristol-Myers Squibb says it will pay a record $1.85 billion to Nektar Therapeutics, a small biotech startup, for rights to its experimental cancer drug, codenamed NKTR-214. Nektar will book 65% of global profits on the drug, should it reach the market, with Bristol getting the other 35%.

Patient Advocate Says Novartis’ $475,000 Breakthrough Should Cost Just $160,000

David Mitchell, 67, says he’s sure that Novartis’ Kymriah is a breakthrough medicine, and that he will need a similar medicine to treat his own blood cancer. He’s sure of something else, too: Novartis is charging too much.

Why A Gene Therapy Pioneer Is Raising Concerns About Treatments He Championed

"I recognize the fact that these are limited numbers [of animals], and in fact that studies were not designed to evaluate safety," Wilson says. "But the fact is, we observed the toxicity with that limited number, which is, from my point of view, even more worrisome."

Bristol’s Weird ‘Win’

Bristol had what it said was some good news this morning. But investors were left with more questions than answers.

Despite Doubters, Moderna Raises $500 Million, Is Now Worth $7.5 Billion

Moderna Therapeutics, a biotechnology firm that is developing drugs that work on a genetic messaging system that is essentially to all living cells, has raised $500 million from a group of new and current investors.

Vertex Picks ‘Impressive’ Cystic Fibrosis Drugs To Aim For A Multibillion-Dollar Market

Vertex Pharmaceuticals has picked two cystic fibrosis drugs to test in combination with its existing CF medicine, Kalydeco, as part of two different three-drug combinations aimed at helping as many as 90% of patients with cystic fibrosis. (Vertex's current offerings can treat half.)

Sanofi CEO: $16 Billion Deal Binge Does Not Represent A Change In Strategy

"We're not buying aggressively," says Olivier Brandicourt, who took over as Sanofi's chief executive in 2015. "We have exactly the same financial discipline we had initially."

Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker

TMunity says it is raising $100 million from investors including Sean Parker's Parker Institute for Cancer Immunotherapy, drug giant Gilead Sciences and Ping An Ventures, the venture arm of China's largest insurance company.

New York City Puts Up $100 Million To Create A Biotech Hub

New York City's government is today asking for proposals on how to use $100 million in funds and city land to create a "life sciences hub" with the goal of making the city competitive with Boston and San Francisco as a place to start biotechnology companies.

Non-Profit Says $850,000 Gene Therapy Is At Least Twice As Expensive As It Should Be

The non-profit Institute for Clinical Evaluation and Review (ICER) says that undisputed breakthrough should cost $400,000 at most, and perhaps $200,000. At that price, would it even exist?

Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018

Inventors, investors and fundraisers from the pharmaceutical industry arrived at the annual J.P. Morgan Healthcare Conference, their annual kickoff party, with lots of questions. They're probably leaving with them, too.

The Winners And Losers Of JP Morgan Monday

The winner? They weren't even there. The loser was Axovant.

Illumina Unveils $20,000 Desktop Sequencer Aimed At Sequencing Germs

Illumina, the dominant maker of DNA sequencers that are used in drug discovery, medicine, and biological research, is unveiling a new toy: A $19,900, one-cubic-foot box that puts DNA sequencing in the reach of many more scientists.

Bill Gates Tells Healthcare’s Capitalists How To Save Five Million Kids

Gates is giving executives, bankers and investors at the year's biggest healthcare industry gathering an assignment list for improving the world, and an offer to help them do so.

Celgene’s $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?

The Impact deal is a window into two big potential shifts. Good: increasing power for the people who invent drugs, compared to those who raise money for them. Bad: innovation in the pharmaceutical industry is increasingly resulting in lots of me-too competition

Drug Company Consortium To Sequence The Genes Of 500,000 Britons Over Next Two Years

In one of the largest efforts to create human genetic data, a consortium of pharmaceutical companies led by the Tarrytown, N.Y.-based firm Regeneron Pharmaceuticals will sequence the genes of 500,000 volunteers from the United Kingd...

Spark Therapeutics Sets Price Of Blindness-Curing Gene Therapy At $850,000

A new drug, Luxturna, literally allows blind people to see. It does it by using a virus to insert new genes into patients’ eyes. This morning, Luxturna’s maker, Spark Therapeutics, is announcing the cost of this medical miracle: $425,000 per eye, or $850,000 a year.

A Market Cynic’s Biotech Year In Review

The world looks different through a stock screen. It’s certainly true when it comes to healthcare stocks.

Copyright © 2015 Regator, LLC